Abstract
The safety of the use of medications in adolescents and children to treat bipolar disorder has not been extensively studied. The prevalence of bipolar disorder in children and adolescents is unknown due to the lack of completed large-scale epidemiological studies. In addition, the diagnosis of this disorder is still questionable in this age group because the same explicit diagnostic criteria used in adults potentially cannot be applied to children and adolescents since the early-onset symptoms often overlap with other disorders such as attention-deficit disorder. The safety of drugs used to treat bipolar disorder is of growing concern, particularly because this population usually requires more than one psychotropic medication to manage the disease. Common side effects seen with several agents, particularly antipsychotics, are somnolence, weight gain, extrapyramidal symptoms, dyslipidemia, type-2 diabetes, and hyperprolactinemia. This review will discuss the most advanced practice guidelines in assessing and treating bipolar disorder in children and adolescents, the safety and effectiveness of the drugs currently used based on clinical trials and post-marketing surveillance, and the risks versus benefits associated with their use.
Keywords: Bipolar disorder, drug safety, pediatrics and adolescents.
Current Drug Safety
Title: Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Volume: 1 Issue: 3
Author(s): Pamela C. Heaton, Colleen M. Garlick and Doan Tran
Affiliation:
Keywords: Bipolar disorder, drug safety, pediatrics and adolescents.
Abstract: The safety of the use of medications in adolescents and children to treat bipolar disorder has not been extensively studied. The prevalence of bipolar disorder in children and adolescents is unknown due to the lack of completed large-scale epidemiological studies. In addition, the diagnosis of this disorder is still questionable in this age group because the same explicit diagnostic criteria used in adults potentially cannot be applied to children and adolescents since the early-onset symptoms often overlap with other disorders such as attention-deficit disorder. The safety of drugs used to treat bipolar disorder is of growing concern, particularly because this population usually requires more than one psychotropic medication to manage the disease. Common side effects seen with several agents, particularly antipsychotics, are somnolence, weight gain, extrapyramidal symptoms, dyslipidemia, type-2 diabetes, and hyperprolactinemia. This review will discuss the most advanced practice guidelines in assessing and treating bipolar disorder in children and adolescents, the safety and effectiveness of the drugs currently used based on clinical trials and post-marketing surveillance, and the risks versus benefits associated with their use.
Export Options
About this article
Cite this article as:
Heaton C. Pamela, Garlick M. Colleen and Tran Doan, Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934396
DOI https://dx.doi.org/10.2174/157488606777934396 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry New Approaches for the Treatment of Chagas Disease
Current Drug Targets Respiratory Gas Exchange During Exercise in Children with Congenital Heart Disease: Methodology and Clinical Concepts
Current Respiratory Medicine Reviews Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Current Pharmaceutical Design Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design IRAKs: Key Regulatory Kinases of Innate Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Selectivity Problems with Drugs Acting on Cardiac Na<sup>+</sup> and Ca<sup>2+</sup> Channels
Current Medicinal Chemistry Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry MicroRNA in Aging: From Discovery to Biology
Current Genomics Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews 10 Years of SELDI: What Have we Learnt?
Current Proteomics HGF as Angiogenic Factor and Therapeutic Approach
Current Signal Transduction Therapy Antisense Oligonucleotide-Mediated Exon Skipping for Duchenne Muscular Dystrophy: Progress and Challenges
Current Gene Therapy Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry Criteria for Creating and Assessing Mouse Models of Diabetic Neuropathy
Current Drug Targets Evaluation of the Antioxidant and Antidiabetic Potential of the Poly Herbal Formulation: Identification of Bioactive Factors
Cardiovascular & Hematological Agents in Medicinal Chemistry Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews